Insider Selling: Invivyd (NASDAQ:IVVD) Insider Sells 20,679 Shares of Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Robert Allen III sold 20,679 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $0.72, for a total transaction of $14,888.88. Following the transaction, the insider owned 195,808 shares of the company’s stock, valued at approximately $140,981.76. The trade was a 9.55% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Invivyd Stock Performance

Shares of NASDAQ IVVD traded up $0.13 during midday trading on Tuesday, reaching $0.87. The stock had a trading volume of 7,732,095 shares, compared to its average volume of 3,061,089. The firm has a market cap of $255.75 million, a price-to-earnings ratio of -2.63 and a beta of 0.71. Invivyd, Inc. has a twelve month low of $0.48 and a twelve month high of $3.07. The company’s 50 day moving average price is $0.77 and its 200 day moving average price is $1.23.

Invivyd (NASDAQ:IVVD) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.03). Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%.The firm had revenue of $14.29 million for the quarter, compared to analyst estimates of $14.40 million. Equities analysts forecast that Invivyd, Inc. will post -0.52 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Invivyd

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Invesco Ltd. increased its stake in Invivyd by 190.6% in the first quarter. Invesco Ltd. now owns 108,999 shares of the company’s stock valued at $66,000 after purchasing an additional 71,485 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of Invivyd by 2,051.0% during the 1st quarter. AQR Capital Management LLC now owns 410,711 shares of the company’s stock worth $249,000 after purchasing an additional 391,617 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Invivyd in the 2nd quarter valued at about $158,000. Jane Street Group LLC acquired a new stake in shares of Invivyd in the 2nd quarter valued at about $147,000. Finally, Vanguard Group Inc. increased its position in Invivyd by 46.7% in the 3rd quarter. Vanguard Group Inc. now owns 5,762,894 shares of the company’s stock valued at $6,339,000 after buying an additional 1,834,970 shares in the last quarter. 70.36% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on IVVD. Wall Street Zen downgraded Invivyd from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Invivyd in a research report on Friday, July 24th. HC Wainwright reaffirmed a “buy” rating on shares of Invivyd in a research note on Tuesday. Finally, BTIG Research reiterated a “buy” rating on shares of Invivyd in a report on Tuesday, July 7th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Invivyd currently has an average rating of “Hold” and a consensus target price of $8.00.

Key Stories Impacting Invivyd

Here are the key news stories impacting Invivyd this week:

• Neutral Sentiment: Robert D. Allen III, Jill Andersen, CFO William E. Duke, Julie Green, and Timothy Edward Lee each sold shares at prices of approximately $0.72 or $0.84. The sales reduced each insider’s direct holdings by roughly 9% to 11%. SEC insider transaction filing
• Neutral Sentiment: The filings state that the transactions were made to cover tax-withholding obligations tied to the vesting of equity awards. Because the sales were not described as discretionary reductions or based on a negative outlook, they are less concerning than open-market sales intended to exit positions. SEC insider transaction filing
• Negative Sentiment: The concentration of sales by multiple insiders may nevertheless create a modest overhang for Invivyd stock, particularly given the company’s small market capitalization and recent elevated trading volume. However, the disclosed tax-related purpose limits the bearish signal.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.